NewsRoom Articles - Page 88 of 247

MondayNov 06, 2023 2:17 pm

Sex Hormones Could Influence Alzheimer’s Development, Researchers Say

University of Western Ontario researchers have discovered that sex hormones may play a role in the development of Alzheimer’s disease. The neurodegenerative condition affects roughly 32 million people globally and is characterized by disruptive symptoms such as poor judgment, memory loss and loss of sense of initiative. With two-thirds of Alzheimer’s patients being women, researchers from the University of Western Ontario sought to understand the role of female sex hormones in how the disease develops in the brain. Some researchers posit that women develop Alzheimer’s disease at higher rates because they tend to live longer than men, while others say…

MondayNov 06, 2023 9:00 am

Renovaro Biosciences Inc. (NASDAQ: RENB) Announces Three New Members to Board of Directors as Definitive Agreement with GEDiCube Announced

Renovaro added Avram Miller, Leni Boeren, Ruud Hendriks, to the company's board of directors The three additions bring extensive financial backgrounds that will help as the company ventures into the new agreement with GEDiCube and Renovaro AI branding Avram Miller believes that Renovaro Bioscience, combined with GEDiCube, has the key elements to play a significant role in transforming AI's impact on medicine Renovaro Biosciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, recently announced a definitive agreement to combine with the advanced AI Company GEDiCube Intl Ltd., rebranding…

FridayNov 03, 2023 12:57 pm

Australian Study Finds Way to Detect Parkinson’s Prior to Symptom Onset

New research has demonstrated that it is possible to detect signs of Parkinson’s disease through the introduction of a synthetic compound into patients’ bodies. The research was carried out by scientists at the Florey Institute and Austin Health in Australia. The focus of the research was to highlight the changes in the brain that marked disease progression before patients began to present with other symptoms. For their study, the scientists recruited 26 patients with Parkinson’s disease, 11 with rapid eye movement (REM) sleep behavior disorder and 12 others who made up the control group. REM sleep behavior disorder is common…

FridayNov 03, 2023 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) PRV Sale Prospects Strengthened by Recent Industry Developments

PaxMedica, with the help of financial services firm Bourne Partners, is actively exploring presale of its Priority Review Voucher (“PRV”), highly valuable in the pharmaceutical marketplace once it gets formal approval from the FDA The move is the next step in PaxMedica's ongoing commitment to advancing innovative healthcare solutions for autism patients worldwide Similar successful endeavors in the pharmaceutical landscape have demonstrated lucrative potential PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has set its sights on an exciting potential opportunity. With the engagement of Bourne Partners, a prominent financial services firm specializing in…

ThursdayNov 02, 2023 1:05 pm

Potential Complications of Untreated Psoriasis

Psoriasis is a skin condition that causes individuals to develop a rash with scaly, itchy patches on their elbows, knees, trunk and scalp. This chronic illness, which may start off as a few itchy patches, can severely affect an individual’s quality of life. Psoriasis is often accompanied by chronic inflammation, which affects those with mild and severe cases alike. Experts agree that in the absence of a cure, proper treatment is required to manage the condition. Below we look at what happens when psoriasis remains untreated and any complications that may arise from undertreating or not treating the condition. What…

WednesdayNov 01, 2023 10:55 am

Alarming Data Highlights Gaps in Treating People with Chronic HBV

Hepatitis B is a liver infection caused by the hepatitis B virus. This disease, which can be prevented via vaccine, spreads when blood or other body fluids from an infected individual enter the body of another. Having chronic hepatitis B increases an individual’s risk of developing cirrhosis, liver cancer or liver failure. New research, which evaluated a cohort of adult veterans in America, has determined that only about one-half started on antiviral therapy. The study was led by clinical associate professor Robert J. Wong of the Stanford University School of Medicine. The researchers’ aim was to understand chronic hepatitis B-related…

TuesdayOct 31, 2023 2:54 pm

Brand Metrics e-Commerce Companies Need to Watch

Brand metrics are qualitative and quantitative measurements markets use to analyze and track the perception, performance and strength of a brand. These assessments allow marketers to gain insight into their brand awareness, loyalty and health among a company’s target audience and general market. With competition in the e-commerce sector getting increasingly fierce by the year, proper brand positioning can help e-commerce companies stand out from the pack, more effectively attracting and retaining customers over the long-term. Marketers can use brand metrics to learn how customers feel about their company and its products, and how likely they are to purchase specific…

MondayOct 30, 2023 11:37 am

Study Identifies Immune Cells Responsible for Severe Asthma

Researchers from the University of Southampton, United Kingdom and La Jolla Institute for Immunology (LJI) have identified a group of immune cells that may be responsible for severe asthma. Identified as cytotoxic CD4+ tissue-resident memory T cells, these cells congregate in the lungs and seem to have the ability to cause the harm associated with later development of asthma. Researchers say these immune cells are especially prevalent in men and note that men who are diagnosed with asthma after age 40 often have high counts of this specific T cell in their lungs, which increases their odds of developing severe…

MondayOct 30, 2023 9:45 am

Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study

Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS In 2019, Clene’s drug candidate, CNM-Au8(R), was selected for the HEALEY ALS Platform Trial, with enrollment commencing in the summer of 2020 Over the years since, Clene has consistently released additional data from the Trial, most recently reporting significant long-term survival improvement among patients treated with CNM-Au8 compared to PRO-ACT historical controls The company also announced the publication of a peer-reviewed study in the nanotechnology-focused journal Small; the study describes CNM-Au8’s mechanism of action Clene received a $45.1…

MondayOct 30, 2023 9:00 am

Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial

Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial The study, which explored Lomecel-B(TM)’s effects on mild Alzheimer’s disease, met the primary endpoint of safety on statistical and medical assessment Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, just announced positive top-line results from its CLEAR MIND Phase 2a clinical trial for treating mild Alzheimer’s disease. Most notably, the primary endpoint of safety was met based on statistical and medical assessment, with only one Serious Adverse…